Oragenics مُضاعَف الربحِية 2024

ماذا تفعل Oragenics؟

Oragenics Inc is a biopharmaceutical company that focuses on the development of innovative technologies and products for the prevention and treatment of oral and systemic infectious diseases. The company was founded in 1996 as a private company and has since had an impressive track record in the development of diagnostic tools and therapeutics for various diseases in different fields. The company's business model is based on the identification and development of therapeutics that leverage innovative technologies such as bacterial toxins and probiotics. Their products aim to address both the causes of disease formation and the symptoms, contributing to improved patient well-being. Oragenics maintains partnerships and collaborations with other companies and research institutions to enhance its research and development efforts. The company is divided into multiple divisions, including the development of probiotic bacterial groups with specific immunotherapeutic functions, the development of biopharmaceutical products for the treatment of infectious diseases, and the development of diagnostics and screening tools for identifying oral infections. Oragenics has developed a range of products and technologies that can contribute to the improvement of oral and overall health, including a Streptococcus mutans detection system for dentists to identify and combat bacteria in the patient's mouth. One notable product is the TerraCoV2 COVID-19 vaccine, developed in collaboration with the National University of Singapore. Overall, Oragenics Inc has a remarkable track record in the development of innovative technologies and products, emphasizing product quality, rational manufacturing, and a wide range of medical devices. The company works closely with partners and collaborators to intensify its research and development efforts and provide innovative solutions and products. Oragenics ist eines der beliebtesten Unternehmen auf Eulerpool.com.